Reyon Pharmaceutical issues KRW 10 billion private convertible bond

• Reyon Pharmaceutical set a KRW 10 billion private placement of 5th unsecured, zero-coupon convertible bonds.
• Proceeds earmarked for working capital.
• Bonds mature Oct. 28, 2031. Redemption at 115.9274% of face value if not converted.
• Conversion price set at KRW 10,170 per share for 983,284 common shares, equal to 5.09% of outstanding stock.
• Conversion window runs from Oct. 28, 2027 to Sept. 28, 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008000695), on October 08, 2026, and is solely responsible for the information contained therein.